PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 20250 citationsOpen Access

Supplementary Figure 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

View Full Paper
MUMireia Uribe‐HerranzAOAina Oliver‐CaldésNMNeus Martínez-Micaelo

Key Points

  • Significant differences in gut microbiome profiles were observed at baseline and 12 months post-CAR-T therapy.
  • Principal coordinates analysis showed varying bacterial community compositions over time, indicating dynamic changes.
  • Partial least square-discriminant analysis identified top discriminating parameters related to microbiome health in patients.
  • Results highlight potential microbiome influences on the effectiveness of CAR-T therapy in treating multiple myeloma.

Abstract

Supplementary Figure 16. Comparison of gut microbiome profiles in MM patients from the first cohort at baseline (apheresis day) and 12 months post–CAR-T-cell infusion. (A) Principal coordinates analysis (PCA) of bacterial community composition at baseline (apheresis day) vs 12 months post CAR-T cell infusion microbiome in MM patients. (B) Variable importance in projection (VIP) scores from partial least square-discriminant analysis (PLS-DA) identifying the top 10 discriminating parameters from 16sRNA metagenomics. Scores plot of PLS-DA based on metagenomics of samples 12 months post-infusion (purple, n = 4) and at baseline (blue, n = 4) from paired patients. Colored dots illustrate individual samples. Axes are labeled with the first and second components and their respective percentages of explained variance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Uribe‐Herranz et al. (2025) studied this question.

synapsesocial.com/papers/68c189ca9b7b07f3a0612eb3https://doi.org/10.1158/2643-3230.30040909
Ask AI
Helpful
Bookmark
Share
View Full Paper